Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9Â mg extended-release tablets in patients with active left-sided ulcerative colitis

Budesonide-MMX® 9 mg tablets induced a fast and significant clinical improvement of active left-sided UC without suppression of adrenocortical functions and without important toxicity EudraCT number 2004-000896-33.